Dr. Gordon H. Guyatt, McMaster University
Dr. Tarry Ahuja, CADTH
Heather Logan, CADTH
The magnitude of the COVID-19 pandemic globally is generating considerable interest in options to prevent infection and minimize the impact if infection occurs. Pre-exposure prophylaxis and post-exposure treatment with a group of drugs called antivirals, sometimes in combination with an antibiotic, have been the subject of public debate and, at times, significant media reporting. Join CADTH on Friday, May 29, 2020, where they will provide the evidence on two specific antiviral treatments that have been widely discussed — hydroxychloroquine (with or without the antibiotic azithromycin) and remdesivir. You’ll also learn about the clinical trials underway on the use of antivirals in preventing and treating COVID-19.
Date: Friday, May 29, 2020
Time: 12:00 p.m. to 12:45 p.m. EDT
To participate, please register (there is no cost). After registering, you will receive a confirmation email with information about how to join the webinar.
If you have any questions about the lecture or how to register, please contact email@example.com.
* CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs and medical devices in our health care system. CADTH receives funding from Canada’s federal, provincial, and territorial governments, with the exception of Quebec. *